Aavia, the women’s health app and data platform, has published a report drawing on more than 250 million lived-experience data points from approximately 150,000 members who log health indicators an average of four times per week. The findings challenge several clinical assumptions about how hormonal conditions present and how medications interact with the hormone cycle.
The core argument: The hormone cycle has been treated as noise in health data when it should be treated as a vital signal. The drugs prescribed to women, the AI models being built to personalize their health, and the clinical trial designs used to evaluate new treatments were all built on data that treats female biology as a constant. Aavia’s dataset is structured around the opposite premise – every data point is anchored to cycle phase.
Among the most striking findings:
Aavia’s algorithms flag PMDD in under 100 days from the start of logging. The healthcare system takes an average of 12 years to diagnose it. The platform identifies condition-specific “symptom fingerprints” – distinct patterns of symptom co-occurrence that differ meaningfully between PMDD, PCOS, PMS, and baseline populations, visible months before a clinical diagnosis.
The report also challenges the clinical framing of PMDD as a purely luteal-phase condition, showing elevated symptom burden across every phase of the cycle – which means current trial designs that measure outcomes only within the luteal window are systematically undercounting the full condition burden.
On medications, Aavia tracked over 1,400 members for 12 months following birth control initiation, revealing a month-one “shock” spike in symptoms that differs by method – data that doesn’t appear in any package insert. Copper IUD users experienced a 100% increase in menstrual cramps in month one before declining to below baseline by month 12.
The report also flags what Aavia calls the most urgent open question in women’s metabolic health: How GLP-1s interact with the hormone cycle. With a 7x increase in GLP-1 prescriptions among women with PCOS since 2021, there is currently no clinical data on whether these drugs affect cycle regularity, worsen cycle-related symptoms, or differ in efficacy depending on cycle phase.
Aavia’s dataset occupies a window that the healthcare system largely ignores: The years between menarche and preconception, when cycles first become irregular, mood shifts are attributed to personality rather than hormones, and conditions that take years to diagnose are quietly beginning. The member base is 97% Gen Z and Gen Alpha – women at the ground floor of their reproductive health who will age into employer benefits, diagnostics, and chronic condition management over the next decade.
The report positions Aavia not as a consumer app but as a data infrastructure layer with commercial applications across pharma and clinical trials (pre-diagnostic recruitment, cycle-anchored efficacy data), AI and health data platforms (the training layer that corrects cycle-agnostic bias), virtual care (between-visit behavioral signal), wearables (the subjective context layer that makes physiological signals meaningful), and performance and behavior change platforms.
The full report is available at aavia.io.
